Recently, Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “Olymvax”) and its subsidiary Chongqing Yuanlun Biotechnology Co., Ltd. signed a cooperation agreement with Chongqing National Swine Technology Innovation Center and Chongqing Academy of Animal Sciences to jointly build the “R&D Laboratory for Fully Human Antibody Drugs Against Major Infectious Diseases”. This cooperation will deeply integrate the Company’s industrialization advantages with the innovation resources of scientific research institutions, jointly tackle key problems in the R&D and industrial application of antibody drugs for infectious diseases, and build a first-class joint laboratory for infectious antibody drug R&D in China.
Chongqing National Swine Technology Innovation Center is the first national-level technology innovation center in the national agricultural sector. With Chongqing Academy of Animal Sciences as the main body, it has formed a number of innovative teams led by academicians and experts, and produced a number of landmark major scientific research achievements. The Center’s unique fully human antibody pig technology platform uses gene-edited pig models to achieve large-scale production of fully human antiserum, opening up a brand-new R&D path to address the problem of super drug-resistant bacteria.
As the leading institution for the construction of Chongqing National Swine Technology Innovation Center, Chongqing Academy of Animal Sciences owns an internationally leading fully human antibody mouse technology platform. By using gene editing technology to break through the limitations of traditional animal models, it can quickly obtain fully human candidate antibodies with high affinity and low immunogenicity. Combined with in-depth mining of massive data through algorithms, it can effectively shorten the target verification cycle and successfully accelerate the whole process from basic research to preclinical development.
Focusing on the field of super bacteria, Olymvax has pioneered an innovative model of “parallel development of dual technology platforms” to address the difficult problem of hospital-acquired super bacteria prevention and treatment in clinical practice. This cooperation will help the Company form a multiple prevention and treatment plan of “Vaccines + Monoclonal Antibody Drugs + Antiserum”, laying a solid foundation for building a complete product matrix for drug-resistant bacteria prevention and treatment. The Company will continue to tackle multiple super bacteria causing severe hospital infections, build core competitiveness in the super bacteria field, and promote the sustainable and high-quality development of the enterprise.